Top

Published in:

Open Access 01-04-2013 | Research Paper

Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy

Authors: Takaaki Tanaka, Yoshihiro Yui, Norifumi Naka, Toru Wakamatsu, Kiyoko Yoshioka, Nobuhito Araki, Hideki Yoshikawa, Kazuyuki Itoh

Published in: Clinical & Experimental Metastasis | Issue 4/2013

Abstract

Osteosarcoma (OS) is the most common malignant bone tumor and the prognosis depends on pulmonary metastases, which arise from multi-step progression of malignant tumors. We herein aimed to clarify the critical step of pulmonary metastasis using the syngeneic mouse spontaneous highly metastatic OS LM8 and parental Dunn cell lines, to identify new candidate molecules to suppress pulmonary metastasis. We first investigated the chronological detection of circulating tumor cells (CTCs) from mice with either cell line. LM8 CTCs appeared faster, at a higher rate and with a greater number compared to Dunn CTCs. Cultured cells from CTCs of LM8 showed higher proliferative ability than cells from the primary site in suspension culture, which mimicked the environment of the bloodstream for CTCs. The proliferative ability of LM8 cells was also higher than that of Dunn cells in 3D collagen culture with low stiffness (−150 Pa; close to conditions in the lung). We next focused on the extravasation step. LM8 showed higher migration ability compared to Dunn with transendothelial migration assay. We also found a disruption in endothelial barrier function throughout co-culture with LM8 using time-lapse imaging. In addition, LM8 secreted high levels of vascular endothelial growth factor (VEGF), while VEGF signal inhibition with a small molecule tyrosine kinase inhibitor (pazopanib) decreased disruption of the vascular barrier and transendothelial migration of LM8. Finally, daily oral administration of pazopanib reduced the rate and size of pulmonary metastasis in vivo. Collectively, these results show anti-VEGF therapy as a candidate for pulmonary metastasis of OS.

Available only for authorised users

Wada T, Isu K, Takeda N et al (1996) A preliminary report of neoadjuvant chemotherapy NSH-7 study in osteosarcoma: preoperative salvage chemotherapy based on clinical tumor response and the use of granulocyte colony-stimulating factor. Oncology 53(3):221–227PubMedCrossRef

Kager L, Zoubek A, Potschger U et al (2003) Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21(10):2011–2018PubMedCrossRef

Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 3(6):453–458PubMedCrossRef

Gapta GP, Massagué J (2006) Cancer metastasis: building a framework. Cell 127(4):679–695CrossRef

Sahai E (2007) Illuminating the metastatic process. Nat Rev Cancer 7(10):737–749PubMedCrossRef

Chiang AC, Massagué J (2008) Molecular basis of metastasis. N Engl J Med 359:2814–2823PubMedCrossRef

Sethi N, Kang Y (2011) Unravelling the complexity of metastasis—molecular understanding and targeted therapies. Nat Rev Cancer 11(10):735–748PubMedCrossRef

Asai T, Ueda T, Itoh K et al (1998) Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 76(3):418–422PubMedCrossRef

Dunn TB, Andervont HB (1963) Histology of some neoplasms and non-neoplastic lesions found in wild mice maintained under laboratory conditions. J Natl Cancer Inst 31:873–901PubMed

10.

Yui Y, Itoh K, Yoshioka K et al (2010) Mesenchymal mode of migration participates in pulmonary metastasis of mouse osteosarcoma LM8. Clin Exp Metastasis 27(8):619–630PubMedCrossRef

11.

Sotobori T, Ueda T, Myoui A et al (2006) Bone morphogenetic protein-2 promotes the haptotactic migration of murine osteoblastic and osteosarcoma cells by enhancing incorporation of integrin beta1 into lipid rafts. Exp Cell Res 312(19):3927–3938PubMedCrossRef

12.

Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8(5):329–340PubMedCrossRef

13.

Yu M, Stott S, Toner M et al (2011) Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 192(3):373–382PubMedCrossRef

14.

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669–676PubMedCrossRef

15.

Weis S, Cheresh DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437(7058):497–504PubMedCrossRef

16.

Weis S, Cui J, Barnes L et al (2004) Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 167(2):223–229PubMedCrossRef

17.

Kaya M, Wada T, Akatsuka T et al (2000) Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6(2):572–577PubMed

18.

Kaya M, Wada T, Nagoya S et al (2009) The level of vascular endothelial growth factor as a predictor of a poor prognosis in osteosarcoma. J Bone Joint Surg Br 91(6):784–788PubMedCrossRef

19.

Poste G, Fidler IJ (1980) The pathogenesis of cancer metastasis. Nature 283(5743):139–146PubMedCrossRef

20.

Kumar R, Knick VB, Rudolph SK et al (2007) Pharmacokinetic–pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6(7):2012–2021PubMedCrossRef

21.

Miroshnikova YA, Jorgens DM, Spirio L et al (2011) Engineering strategies to recapitulate epithelial morphogenesis within synthetic three-dimensional extracellular matrix with tunable mechanical properties. Phys Biol 8(2):026013PubMedCrossRef

22.

Butcher DT, Alliston T, Weaver VM (2009) A tense situation: forcing tumour progression. Nat Rev Cancer 9(2):108–122PubMedCrossRef

23.

Nagrath S, Sequist LV, Maheswaran S et al (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450(7173):1235–1239PubMedCrossRef

24.

Liu MC, Shields PG, Warren RD et al (2009) Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 27(31):5153–5159PubMedCrossRef

25.

Matsusaka S, Chìn K, Ogura M et al (2009) Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer Sci 101(4):1067–1071CrossRef

26.

Matsusaka S, Suenaga M, Mishima Y et al (2010) Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer. Cancer Sci 102(6):1188–1192CrossRef

27.

Sandri MT, Zorzino L, Cassatella MC et al (2010) Changes in circulating tumor cell detection in patients with localized breast cancer before and after surgery. Ann Surg Oncol 17(6):1539–1545PubMedCrossRef

28.

Cohen SJ, Punt CJ, Iannotti N et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26(19):3213–3221PubMedCrossRef

29.

de Bono JS, Scher HI, Montgomery RB et al (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14(19):6302–6309PubMedCrossRef

30.

Cifone MA, Fidler IJ (1980) Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc Natl Acad Sci USA 77(2):1039–1043PubMedCrossRef

31.

Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4(6):448–456PubMedCrossRef

32.

Pantel K, Alix-Panabières C (2007) The clinical significance of circulating tumor cells. Nat Clin Pract Oncol 4(2):62–63PubMedCrossRef

33.

Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342PubMedCrossRef

34.

Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666–2676PubMedCrossRef

35.

Kelly WK, Halabi S, Carducci M et al (2012) Randomized, double-blind, placebo-controlled phase iii trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30(13):1534–1540PubMedCrossRef

36.

Ebos JM, Lee CR, Cruz-Munoz W et al (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15(3):232–239PubMedCrossRef

37.

Paez-Ribes M, Allen E, Hudock J et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3):220–231PubMedCrossRef

38.

Steeg PS, Anderson RL, Bar-Eli M et al (2009) Preclinical drug development must consider the impact on metastasis. Clin Cancer Res 15(14):4529–4530CrossRef

Title: Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy
Authors: Takaaki Tanaka
Yoshihiro Yui
Norifumi Naka
Toru Wakamatsu
Kiyoko Yoshioka
Nobuhito Araki
Hideki Yoshikawa
Kazuyuki Itoh
Publication date: 01-04-2013
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 4/2013
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-012-9543-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Matrix detachment and proteasomal inhibitors diminish Sulf-2 expression in breast cancer cell lines and mouse xenografts

Smad interacting protein 1 (SIP1) is associated with peritoneal carcinomatosis in intestinal type gastric cancer

LIM kinase inhibition reduces breast cancer growth and invasiveness but systemic inhibition does not reduce metastasis in mice

The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review

Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus

Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer